Severe Anaemia (Exceptional Blood Loss) and HBOT
Hyperbaric oxygen therapy serves as a bridge therapy when life-threatening anaemia cannot be corrected with blood transfusion, most often because of religious refusal of blood products (commonly Jehovah's Witness patients), unavailability of compatible blood, or rare blood types. It dissolves enough oxygen directly into plasma to meet the body's basic metabolic oxygen demand independent of haemoglobin, sustaining tissue viability until red-cell mass recovers or compatible blood becomes available. Severe anaemia is recognised by Health Canada as one of the 14 conditions for which provincial health insurance covers HBOT at hospital-based programmes.
Quick Answer
Does HBOT help severe anaemia (exceptional blood loss)? Hyperbaric oxygen therapy serves as a bridge therapy when life-threatening anaemia cannot be corrected with blood transfusion, most often because of religious refusal of blood products (commonly Jehovah's Witness patients), unavailability of compatible blood, or rare blood types. It dissolves enough oxygen directly into plasma to meet the body's basic metabolic oxygen demand independent of haemoglobin, sustaining tissue viability until red-cell mass recovers or compatible blood becomes available. Severe anaemia is recognised by Health Canada as one of the 14 conditions for which provincial health insurance covers HBOT at hospital-based programmes.
What Is Severe Anaemia (Exceptional Blood Loss)?
Severe anaemia, in the hyperbaric context, refers to haemoglobin so low that oxygen delivery to tissues is critically inadequate and the patient is at imminent risk of cardiac, neurological, or multi-organ injury. The clinical thresholds vary by patient (baseline cardiac function, comorbidities, ongoing oxygen demand), but haemoglobin values below 5 to 6 g/dL with continuing decompensation are typical referral triggers, with case reports of survival from values below 3 g/dL when HBOT was added to standard supportive care.
The most common Canadian scenario is a patient who has refused blood transfusion on religious grounds (most often a Jehovah's Witness patient, whose faith proscribes transfusion of whole blood, packed red cells, plasma, platelets, or white cells but typically permits non-blood volume expanders, autologous blood salvage circuits, recombinant erythropoietin, IV iron, and hyperbaric oxygen). Other scenarios include massive obstetric or surgical hemorrhage in a patient with a rare blood type for whom compatible product is unavailable, mass-casualty events where blood inventory is exhausted, and patients with known haemoglobinopathy or autoimmune hemolysis where appropriate blood is not immediately accessible.
The clinical picture is dominated by tissue hypoxia at the cellular level: persistent tachycardia, lactic acidosis, oliguria, altered mentation, ischaemic ECG changes, troponin elevation, and (in severe cases) cardiac arrhythmia. The decompensation can be acute (hours after a major bleed) or sub-acute (days after persistent low-grade loss). HBOT does not replace transfusion and does not directly correct the haemoglobin; it sustains the tissue oxygen delivery long enough for medical erythropoietic support, hemostatic control, or autologous recovery to take effect.
How HBOT Helps
Under normal conditions at sea-level air pressure, the dissolved oxygen content of plasma is approximately 0.3 mL of O2 per 100 mL of plasma, a trivial fraction of the oxygen carried by haemoglobin (approximately 20 mL of O2 per 100 mL of fully saturated arterial blood). When haemoglobin is severely depleted, this dissolved fraction becomes the only meaningful oxygen-delivery pathway, but at 1 atmosphere it is grossly insufficient to meet metabolic demand.
Hyperbaric oxygen therapy at 3.0 ATA on 100 percent oxygen raises the plasma-dissolved oxygen content to approximately 6 mL of O2 per 100 mL of plasma. This is enough to meet the body's basic resting metabolic oxygen demand of approximately 5 mL per 100 mL even with haemoglobin near zero, the principle Boerema demonstrated in his classic 1960 "life without blood" experiments in pigs (which survived complete exchange transfusion of plasma at 3 ATA and recovered after re-transfusion). In the contemporary clinical setting, the goal is not to replace haemoglobin function continuously but to provide intermittent oxygen "loading" through scheduled chamber sessions, sustaining the patient's tissues until red-cell mass recovers.
In parallel, HBOT supports erythropoiesis by stimulating release of erythropoietin and its associated cofactors, reduces ischaemic-reperfusion injury at vulnerable organs (most importantly heart, brain, and kidney) during periods of marginal oxygen delivery, and modulates the systemic inflammatory cascade that accompanies severe anaemia and major hemorrhage. The combination of bridging oxygenation and anti-ischaemic effect is what makes HBOT a clinically meaningful (if uncommonly used) adjunct in this population.
Typical Treatment Protocol
The standard adjunctive protocol is 2.0 to 3.0 ATA on 100 percent oxygen for 90 to 120 minutes per session. Pressure is selected based on the severity of anaemia and the patient's tolerance: 2.4 to 2.8 ATA covers most cases, with 3.0 ATA reserved for the most severe presentations and the shortest practical session lengths to limit oxygen toxicity risk. In life-threatening cases, multiple sessions per 24 hours may be delivered, sometimes back-to-back with brief surface intervals, until the haemoglobin can be supported through medical erythropoietic stimulation (recombinant erythropoietin, IV iron, vitamin B12, folate) and hemostatic control. Total course length varies from one or two sessions to several weeks of daily treatment, depending entirely on how quickly the patient's haemoglobin recovers. The hyperbaric medicine team coordinates closely with hematology, critical care, the surgical team (for ongoing hemostasis), and any patient liaison from the Jehovah's Witness Hospital Liaison Committee where applicable.
Evidence Summary
Level B - Moderate Evidence
Supported by controlled studies and clinical evidence
Key Research Findings
-
Boerema's 1960 Life Without Blood experiments demonstrated that pigs could survive complete exchange transfusion of plasma at 3 ATA hyperbaric oxygen and recover after re-transfusion. This is the foundational mechanistic evidence for HBOT in severe anaemia and is reproducible in modern animal models.
-
At 3.0 ATA on 100 percent oxygen, plasma-dissolved oxygen reaches approximately 6 mL of O2 per 100 mL of plasma, sufficient to meet the body's basic resting metabolic demand of approximately 5 mL per 100 mL even with haemoglobin near zero. This is the quantitative basis for HBOT as a bridge therapy.
-
Multiple case series and case reports document survival of patients with haemoglobin below 3 g/dL using HBOT as part of a bloodless management strategy, including patients managed for religious reasons in Jehovah's Witness centres in Canada, the United States, and Europe.
-
HBOT does not directly raise haemoglobin and is not a replacement for transfusion in patients who can accept blood. Its role is to sustain tissue oxygenation during the period when haemoglobin is critically low and other treatment is taking effect (erythropoietin response, hemostatic control, autologous red-cell regeneration).
-
The frequency and duration of HBOT sessions is individualised based on hemodynamic stability, lactate, end-organ function, and the rate of haemoglobin recovery. Some patients require only one or two sessions; others require daily sessions for weeks.
-
In Canadian hospital programmes, severe-anemia HBOT is typically coordinated as a multi-disciplinary effort involving hematology, critical care, surgery (for ongoing hemostasis), the Jehovah's Witness Hospital Liaison Committee where applicable, and the hyperbaric medicine team.
-
Key supporting studies in the Canada Hyperbarics research database: PMID 42093774, PMID 40676637, PMID 32807666.
Top studies in our database
Highest-evidence-tier studies tagged to this condition in the Canada Hyperbarics research database, ranked by evidence tier (1 = meta-analysis or RCT, 2 = cohort, 3 = case series), most recent first.
-
Tier 2A systematic review of the application of hyperbaric oxygen in the treatment of severe anemia: an evidence-based approach.
Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc · 2005 · Systematic Review
What to Expect from Treatment
Most patients arrive at hospital through the emergency department or are recognised on the surgical or critical-care wards after a major bleed or persistent low-haemoglobin state. The treating team coordinates with the hospital hyperbaric programme as soon as the patient is identified as a candidate, often within hours of the index event. In Ontario, urgent inter-facility transfer can be arranged through CritiCall Ontario at 1-800-668-4357. The patient is typically already on critical-care support (IV access, monitoring, and (sometimes) ventilator) at the point of HBOT initiation.
Hyperbaric sessions for severe anaemia are most commonly delivered in multiplace chambers (large enough to accommodate a stretcher, ventilator, infusion pumps, and a hyperbaric-trained nurse and physician inside the chamber alongside other patients). Some monoplace chambers can accommodate critically ill patients through purpose-designed pass-throughs for IV lines and monitoring leads. Pressurisation takes five to ten minutes, the treatment phase is on 100 percent oxygen at 2.0 to 3.0 ATA for 90 to 120 minutes, and decompression takes another five to ten minutes.
Between sessions, the medical team continues hemostatic control (surgical, endoscopic, or pharmacological), erythropoietic stimulation (recombinant erythropoietin and IV iron are the most commonly used supports in the Jehovah's Witness population), and supportive critical care. The frequency and total number of HBOT sessions is determined day-by-day based on haemoglobin trend, hemodynamic stability, lactate, troponin, and end-organ function. Most patients who survive to discharge return to baseline organ function within weeks, although the recovery from severe anaemia can be prolonged by the rate at which red-cell mass can be regenerated.
Accessing HBOT for Severe Anaemia (Exceptional Blood Loss) in Canada
Severe anaemia, in the hyperbaric sense of life-threatening blood loss where transfusion is not possible, is recognised by Health Canada as one of the 14 conditions for which provincial health insurance covers HBOT at hospital-based programmes. It is uncommon in absolute numbers (a handful of cases per programme per year is typical), but the clinical urgency and the relative rarity of alternative options make it a high-value indication when it presents.
In Ontario, OHIP covers treatment at the three hospital programmes (Toronto General / UHN, Hamilton General Hospital, The Ottawa Hospital). CritiCall Ontario at 1-800-668-4357 is the standard line for inter-facility transfer coordination. In British Columbia, treatment is at Vancouver General Hospital's Leon Judah Blackmore Pavilion, with BC Ambulance critical-care transport for cases originating outside the Lower Mainland. In Alberta, both Misericordia Edmonton (Covenant Health) and the Foothills Medical Centre / AJECCC Calgary (Alberta Health Services) accept severe-anemia referrals with the Alberta hospital billing code 13.99I (per 15 minutes). RAMQ covers treatment at Hôpital du Sacré-Cœur de Montréal and Hôtel-Dieu de Lévis in Quebec. MSI (Nova Scotia), MCP (Newfoundland and Labrador), and Saskatchewan also cover their respective hospital programmes.
For patients in provinces or territories without an in-province hospital programme (Manitoba, New Brunswick, Prince Edward Island, Yukon, Northwest Territories, Nunavut), urgent inter-provincial transfer is arranged through the receiving province's transfer service. Most such cases route to Misericordia Edmonton (for prairie and territorial patients) or to the Ontario hospital programmes. Coordination with the Jehovah's Witness Hospital Liaison Committee, where applicable, is well-established at the major Canadian programmes; the Liaison Committee provides 24/7 patient-advocate support and helps identify acceptable bloodless treatment options.
Provincial Access for Severe Anaemia (Exceptional Blood Loss)
Hyperbaric oxygen therapy for the 14 Health Canada-recognised conditions, including Severe Anaemia (Exceptional Blood Loss), is delivered at the 11 hospital hyperbaric programmes located in seven provinces (Ontario, Quebec, British Columbia, Alberta, Nova Scotia, Newfoundland and Labrador, and Saskatchewan). The six provinces and territories without an in-province hospital programme (Manitoba, New Brunswick, Prince Edward Island, Yukon, Northwest Territories, and Nunavut) route patients to the nearest receiving hospital programme. Use the links below for province-specific coverage, referral pathway, and emergency routing details.
Hospital + Private
OHIP (Ontario Health Insurance Plan)
Hospital Only
MSP (Medical Services Plan)
Hospital + Private
Alberta Health / AHCIP
Hospital Only
RAMQ
Disrupted
Saskatchewan Health Authority
No Hospital Chamber
Manitoba Health
Hospital Only
MSI (Medical Services Insurance)
No Hospital Chamber
Medicare NB
Hospital Only
MCP (Medical Care Plan)
Out-of-Province Referral
Health PEI
Out-of-Province Referral
Yukon Health and Social Services
Out-of-Province Referral
NWT Health and Social Services
Out-of-Province Referral
Nunavut Department of Health
For acute or emergency presentations of Severe Anaemia (Exceptional Blood Loss), call 911 first. The receiving emergency department coordinates urgent transfer to the nearest hospital hyperbaric programme through the relevant provincial transfer network (CritiCall Ontario at 1-800-668-4357, BC Patient Transfer Network, EHS Nova Scotia, or equivalent). For diving-related emergencies, the Divers Alert Network (DAN) emergency hotline is 1-919-684-9111.
Risks and Contraindications
Absolute contraindications to HBOT include untreated pneumothorax (because trapped intrathoracic air expands on decompression and can cause tension pneumothorax), concurrent bleomycin chemotherapy (because hyperbaric oxygen can trigger or accelerate oxygen-induced pulmonary fibrosis), and concurrent disulfiram (because it inhibits superoxide dismutase, the enzyme that neutralises hyperbaric-oxygen-generated free radicals). Prior bleomycin exposure with documented pulmonary clearance is a relative contraindication that requires individualised pulmonary-function review before HBOT. The pneumothorax must be drained before chamber entry. Hemodynamic instability requiring continuous high-dose vasopressor titration is a relative contraindication because chamber-side pump titration is more difficult; modern multiplace chambers accommodate ventilator-dependent and vasopressor-dependent patients with appropriate critical-care support, but the threshold for proceeding requires individual judgement. Severe chronic obstructive pulmonary disease with bullous lung disease and uncontrolled seizure disorder are relative contraindications. None of these are typically allowed to override the hyperbaric decision in a patient with truly life-threatening anaemia and no transfusion option, given the high mortality of untreated severe anaemia.
Frequently Asked Questions
HBOT is used when a patient has life-threatening anaemia and cannot receive blood transfusion. The most common Canadian reasons are religious refusal of blood products (most often by Jehovah's Witness patients), unavailability of compatible blood for a patient with a rare blood type, and (occasionally) mass-casualty events with blood inventory exhaustion. HBOT is not used for moderate or chronic anaemia.
No. HBOT is a bridge therapy, not a replacement for transfusion. It dissolves enough oxygen into plasma to meet basic metabolic demand for the duration of each chamber session, sustaining tissue viability until red-cell mass can recover through medical erythropoietic stimulation, hemostatic control, or autologous recovery. Transfusion remains the standard of care for patients who can accept blood products.
Yes. Severe anaemia, in the hyperbaric sense of life-threatening blood loss where transfusion is not possible, is recognised by Health Canada and covered by every provincial health-insurance plan at hospital-based hyperbaric programmes. OHIP, MSP, AHCIP, RAMQ, MSI, MCP, and Saskatchewan Health all cover treatment at their respective hospital chambers. No prior authorisation is required in an acute presentation.
It varies enormously based on the rate of haemoglobin recovery and the patient's clinical trajectory. Some patients need only one or two sessions to bridge through a critical period; others need daily sessions for two to four weeks. The decision is made day-by-day by the hyperbaric medicine team in consultation with hematology and critical care.
HBOT is one of several modalities used as part of a bloodless management plan for Jehovah's Witness patients. Other components typically include pre-operative optimisation of red-cell mass with recombinant erythropoietin and IV iron, intra-operative blood salvage circuits (when acceptable to the patient under their faith's direction), meticulous surgical hemostasis, and post-operative HBOT if haemoglobin falls into the critical range. The Jehovah's Witness Hospital Liaison Committee can help connect you to surgeons and hyperbaric programmes experienced in bloodless surgery.
In most Canadian centres, the first HBOT session can be delivered within hours of the decision to use it. The receiving emergency department or surgical team contacts the hospital hyperbaric programme directly, and the chamber is typically prepared in parallel with other resuscitation efforts. In Ontario, urgent inter-facility transfer can be arranged through CritiCall Ontario at 1-800-668-4357.
For ventilated or critically ill patients, the chamber session feels like routine ICU care with the addition of pressurisation. Multiplace chambers accommodate stretchers, ventilators, infusion pumps, and a hyperbaric-trained nurse and physician inside the chamber. Pressurisation takes five to ten minutes and feels like an aircraft descent. The treatment phase at 2.0 to 3.0 ATA on 100 percent oxygen lasts 90 to 120 minutes. Decompression takes another five to ten minutes. The patient is continuously monitored throughout.
The hyperbaric environment is generally safe for severely anaemic patients when delivered in a chamber equipped for critical-care support. The main risks are oxygen toxicity (managed with brief air-breaks during longer sessions), barotrauma (managed with pressure-equalisation, occasionally tympanostomy tubes), and the logistical challenges of titrating vasopressors and managing ventilation inside the chamber. The risks are weighed against the high mortality of untreated severe anaemia and are usually acceptable.
Severe-anaemia HBOT requires a multiplace chamber equipped for critical-care support, so it is delivered at the Canadian hospital hyperbaric programmes with such chambers, not necessarily every site. The Canada Hyperbarics verified directory at canadahyperbarics.ca/facilities/ lists all programmes with phone numbers, addresses, and current operational status. In an acute bleed, the local emergency department will arrange the referral; in Ontario, this is coordinated through CritiCall Ontario at 1-800-668-4357. The Jehovah's Witness Hospital Liaison Committee can also help connect patients to bloodless-medicine programmes at major Canadian centres.
In Canada, severe anaemia is one of the 14 Health Canada-recognised conditions for HBOT, so treatment at hospital-based programmes is covered by provincial health insurance (OHIP, MSP, AHCIP, RAMQ, MSI, Saskatchewan Health, MCP) with a physician referral, at no out-of-pocket cost. The only absolute contraindication to HBOT is untreated pneumothorax (trapped intrathoracic air expands on decompression); concurrent bleomycin chemotherapy (oxygen-induced pulmonary fibrosis risk) and concurrent disulfiram (interferes with superoxide dismutase, the enzyme that neutralises hyperbaric-oxygen-generated free radicals) are treated as effectively absolute at most programmes, though the UHMS classifies them as relative contraindications. Relative contraindications include severe haemodynamic instability requiring continuous high-dose vasopressor titration, uncontrolled seizure disorder, severe COPD with bullous lung disease, and uncontrolled claustrophobia. Pregnancy is not a contraindication.